Although previously for ES patients, SPP1 [23], MGST1 [18], and miR34a [24] were considered as markers of ES progression and ES cell sensitivity towards doxorubicin, no additional prognostic factors have been proposed based on individualized treatment options. The gene discussed is SPP1; the disease is Ewing sarcoma.